148905-78-6

148905-78-6 structure

Name: Bexlosteride.
Chemical Name: Bexlosteride
CAS Number: 148905-78-6
Molecular Formula: C₁₄H₁₆ClNO
Molecular Weight: 249.736
Catalog: Research Areas Cancer
Create Date: 2018-06-10 12:39:19
Modify Date: 2025-08-25 20:34:06
Bexlosteride (LY300502) is a benzoquinolinone human type I 5α-reductase inhibitor. Bexlosteride shows metabolic inhibitory, antiproliferative, and antisecretory effects in LNCaP human prostatic adenocarcinoma cell cultures. Bexlosteride can be used for the research of prostatic cancer[1][2].

Name	Bexlosteride
Synonyms	Benzo[f]quinolin-3(2H)-one, 8-chloro-1,4,4a,5,6,10b-hexahydro-4-methyl-, (4aR,10bR)- (4aR,10bR)-8-Chloro-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one 36X732P4P0 bexlostéride (4aR-trans)-8-Chloro-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one Benzo(f)quinolin-3(2H)-one, 8-chloro-1,4,4a,5,6,10b-hexahydro-4-methyl-, trans- Bexlosteride

Description	Bexlosteride (LY300502) is a benzoquinolinone human type I 5α-reductase inhibitor. Bexlosteride shows metabolic inhibitory, antiproliferative, and antisecretory effects in LNCaP human prostatic adenocarcinoma cell cultures. Bexlosteride can be used for the research of prostatic cancer[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others
Target	human type I 5α-reductase[1]
In Vitro	Bexlosteride concentration-dependently inhibits reductive metabolism of [3H-T] in the LNCaP cells, with an IC50 of 5.77 nM[1]. Bexlosteride significantly antagonizes Testosterone-induced stimulation of LNCaP cellular proliferation at concentrations greater than 10 nM, and at 1000 nM completely blocks the mitogenic effects of Testosterone on LNCaP cells[1]. Bexlosteride significantly antagonizes Testosterone -induced PSA secretion at a concentration equal to or greater than 30 nM[1].
References	[1]. Sutkowski DM, et, al. Responses of LNCaP prostatic adenocarcinoma cell cultures to LY300502, a benzoquinolinone human type I 5alpha-reductase inhibitor. Prostate Suppl. 1996;6:62-6. [2]. Farid NA, et, al. Stereoselective disposition of the enantiomers of the benzoquinolinone LY191704, a human type I 5 alpha-reductase inhibitor. Differences between rats and dogs. Drug Metab Dispos. 1996 Oct;24(10):1162-5.

Hazard Codes	Xi